Lan Mo, MD
Hematology & Oncology · New York, NYNPI 1760786388
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,277 of the $55,547 with a category attached, or 63.5%. 40 manufacturers reported payments, led by AstraZeneca at 29.9% of the total. Reporting peaked in 2020 at $12,589 and has fallen 55.8% since, to $5,568 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $154.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Boehringer Ingelheim$7K
- Dova Pharmaceuticals$6K
- Exelixis Inc.$6K
- Eisai Inc.$4K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $13K from 34 others
Across 8 payments — averaging $4743.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$24K
- Astrazeneca UK Limited$9K
- Eli Lilly$5K
What the payments were for
- Consulting fees$35,27764%
- Speaking & faculty fees$9,80018%
- Travel & lodging$2280%
- Food & beverage$10,03118%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,547 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 183 | $3,263,575 |
| LenvimaLenvatinib Mesylate | 16 | $365,764 |
| XtandiEnzalutamide | 24 | $325,694 |
| AlecensaAlectinib Hcl | 15 | $279,485 |
| ImbruvicaIbrutinib | 13 | $212,604 |
| GilotrifAfatinib Dimaleate | 17 | $187,581 |
| Abiraterone Acetate | 52 | $180,856 |
| DopteletAvatrombopag Maleate | 12 | $148,929 |
| EliquisApixaban | 61 | $35,541 |
| Ondansetron OdtOndansetron | 73 | $2,228 |
| Clindamycin Phosphate | 12 | $630 |
| Anastrozole | 24 | $431 |
| Hydroxyurea | 26 | $282 |
| Hydrocortisone | 39 | $257 |
| Prednisone | 60 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $16,587 | $3,263,575183 claims |
| Eisai Inc.Lenvima | $3,709 | $365,76416 claims |
| Astellas Pharma US IncXtandi | $144 | $325,69424 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $125 | $212,60413 claims |
| Boehringer IngelheimGilotrif | $7,383 | $187,58117 claims |
| Dova PharmaceuticalsDoptelet | $5,930 | $148,92912 claims |
| PfizerEliquis | $162 | $35,54161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.